News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ) Zytiga Prostate Cancer Drug Approved in EU


9/7/2011 8:15:19 AM

Johnson & Johnson's prostate cancer drug Zytiga has been approved in the European Union, paving the way for the launch of a new treatment for men whose disease has progressed after chemotherapy, the company said on Wednesday. The decision was expected after European regulators endorsed the treatment in July. J&J's Janssen unit has European rights for the product. Zytiga, or abiraterone, works by blocking the synthesis of testosterone, which can fuel cancer growth.

Read at Reuters
Read at Wall Street Journal
Read at EconomicTimes
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES